Cargando…
Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
BACKGROUND: Few data exist related to the impact of roflumilast on health care utilization. This retrospective study estimated 30-day hospital readmission rates between patients who did and did not use roflumilast among those with COPD hospitalizations. METHODS: Data were from MarketScan, a large US...
Autores principales: | Fu, Alex Z, Sun, Shawn X, Huang, Xingyue, Amin, Alpesh N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435078/ https://www.ncbi.nlm.nih.gov/pubmed/25999706 http://dx.doi.org/10.2147/COPD.S83082 |
Ejemplares similares
-
Posthospital follow-up visits and 30-day readmission rates in chronic obstructive pulmonary disease
por: Fidahussein, Salman S, et al.
Publicado: (2014) -
A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world
por: Wan, Yin, et al.
Publicado: (2015) -
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
por: Moll, Keran, et al.
Publicado: (2015) -
Performance of the LACE index to predict 30-day hospital readmissions in patients with chronic obstructive pulmonary disease
por: Hakim, Maryam A, et al.
Publicado: (2017) -
Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
por: Kim, Kyung Hoon, et al.
Publicado: (2017)